Abstract 55: A Novel Thrombolytic with Anti-inflammatory Properties (JX10) Improves Neurological Outcomes in Acute Lacunar Infarct up to 12 hours After Onset

• DOI: 10.1161/str.56.suppl_1.55
• Publication Date: 2025-01-30T10:21:51Z
• Authors: Edmond Chen; Kuniyasu Niizuma; Fnu Nitika; Keiji Hasumi; Teiji Tominaga; Naoko Nishimura; Shenglin Zhang
• Keywords: Stroke; Acute stroke; Lacunar infarction

Introduction: Approved thrombolytic agents are currently only recommended for acute ischemic stroke (AIS) within 4.5 hours from the last known well (LKW). Hence, there remains an unmet need in treatment of AIS safer and more effective thrombolytics, which can also be administered to a broader population with extended window. JX10 is novel that works by inducing conformational changes plasminogen increase downstream fibrin affinity promote physiological fibrinolysis instead direct activation like tissue activators (t-PA). exerts anti-inflammatory activity through inhibition soluble epoxide hydrolase, may suppress hemorrhagic associated cerebral infarction. In randomized, double-blind, placebo-controlled, dose-escalation phase 2a study conducted Japan, increased vessel recanalization improved neurologic outcomes. This subgroup analysis evaluated safety efficacy participants who presented lacunar infarct. Methods: or placebo was as single intravenous infusion at dose 1, 3, 6 mg/kg patients were ineligible activator thrombectomy 12 h LKW. Safety Efficacy outcomes assessed 90 days. Results: Among enrolled trial, total 25 infarct dosed (JX10 1 group: subject; 3 subjects; 7 14 subjects). mg/kg, pooled groups, group, rates mRS 0–1 0 subject out (0.0%), (33.3%), subjects (42.9%), 4 11 (36.4%), (7.1%), respectively, those 0–2 (100.0%), (57.1%), (63.6%), 2 (14.3%), respectively. Despite small numbers, treated showed trend function days, measured mRS. Symptomatic intracranial hemorrhage not observed any patients. Conclusions: functional outcome infarct, day vs placebo. Findings support further testing larger patient populations.